12 results about "Cytoskeleton" patented technology

This invention discloses the application of a PDLIM2 gene overexpression viral vector in the preparation of drugs for treating podocyte disease, wherein the nucleotide sequence of the PDLIM2 gene is shown in SEQ ID NO:1. This invention is the first to discover and verify the core role of the PDLIM2 gene in podocyte protection, confirming its significant downregulation in DKD and FSGS disease models, and demonstrating through functional experiments that PDLIM2 overexpression can effectively stabilize the podocyte cytoskeleton, inhibit apoptosis, and reduce proteinuria, thus establishing it as a key target gene for the treatment of podocyte disease. This invention is the first to intervene at the gene level in the core link of podocyte damage—cytoskeleton stability. By specifically upregulating the expression of PDLIM2 in podocytes, it directly enhances their intrinsic cytoskeleton support and anti-damage ability, achieving a fundamental shift in treatment strategy from "symptomatic support" to "causal repair."

This invention discloses the pharmaceutical applications of a P2Y11-specific inhibitor and compositions containing it, belonging to the field of biomedical technology. This invention discloses for the first time the use of NF157 in the preparation of drugs related to the treatment of HD5-induced pathogen infection. In combating pathogen infection, NF157 can specifically inhibit the binding of P2Y11 to HD5, thereby eliminating the role of HD5 in regulating cytoskeleton rearrangement and promoting filopodia formation, thus becoming a key link in interrupting pathogen infection. By preventing the formation of filopodia, NF157 effectively blocks the bacterial capture pathway, showing significant intervention effects on some pathogens that lack adhesion devices and flagella and rely on cellular pseudopodia capture for invasion.

The invention provides a molecular self-assembly integrin patch for regulating and controlling mechanical signals of cells as well as a preparation method and application of the molecular self-assembly integrin patch, and an extracellular matrix (ECM) bionic cell patch is constructed through a molecular self-assembly technology. According to the patch, a laminin-derived integrin binding ligand is extended and self-assembled through an N-terminal aromatic amino acid to form a fibrous nano network, and the patch has controllable nano-scale ligand distribution, network viscoelasticity and stability, and can specifically activate integrin beta1 at the top end of MSC (mesenchymal stem cell), so that a mechanical signal is conducted from a cell membrane to a cell nucleus. The process coordinates cytoskeleton reconstruction, nuclear deformation and chromatin rearrangement, and finally drives the MSC to efficiently differentiate into neuron-like cells under the condition of no exogenous gene or chemical induction, so as to express nerve markers such as TUBB3 and present functional characteristics such as spontaneous calcium transient. The cell patch can be widely applied to nerve regeneration, tissue engineering, disease model construction and intelligent biological material development.

The application discloses a kind of drugs for treating glucocorticoid glaucoma.The application finds by experiment, Rho kinase inhibitor can inhibit RhoA-ROCK signal pathway, destroy glucocorticoid-induced cytoskeleton remodeling and reduce extracellular matrix deposition.At the same time, 10 μM or less concentration, no toxic side effects to cell growth, while significantly inhibiting RhoA-ROCK signal pathway.The experimental results suggest that RKI1447 can change the morphology of trabecular meshwork cells and inhibit cell migration, thereby regulating aqueous humor drainage, reducing intraocular pressure, and thereby treating glucocorticoid glaucoma.The application provides the application of Rho kinase inhibitor RKI1447 in the preparation of glucocorticoid glaucoma drugs.

This invention relates to the field of large-scale adipose-derived stem cell culture technology, and discloses a culture medium and method for promoting the efficient expansion of adipose-derived stem cells. The method includes: seeding adipose-derived stem cells in a serum-free basal culture medium and maintaining a normoxic environment; adding an expansion additive composed of a Rho-associated kinase inhibitor and a redox buffer component; during the window period when the ambient oxygen partial pressure decreases from normoxic to hypoxic, using the Rho-associated kinase inhibitor to relieve cytoskeleton tension to induce a physically relaxed cell membrane; and assisting the redox buffer component in constructing a reducing environment on the cell membrane surface in situ. This invention utilizes the dynamic synergy of membrane tension regulation and oxygen stress shielding to neutralize transient damage caused by sudden changes in ambient oxygen partial pressure, avoid transmembrane receptor conformational inactivation, inhibit premature cell aging at the mechanistic level, and ensure long-term stable expansion of adipose-derived stem cells without the need for heterologous protein protection.

This invention discloses Astragalus polysaccharide, extracted from Astragalus membranaceus. The average molecular weight of this Astragalus polysaccharide is 8-12 kDa, and its monosaccharides are mainly composed of galacturonic acid, glucose, galactose, and arabinose. This Astragalus polysaccharide is a GalA-type acidic polysaccharide that effectively reduces the deposition of immune complexes and the release of pro-inflammatory factors in renal tissue by regulating signaling pathways such as cGAS-STING. Simultaneously, it improves glomerular filtration function by stabilizing the podocyte cytoskeleton structure, exhibiting a synergistic protective therapeutic advantage. This invention also discloses a method for preparing this Astragalus polysaccharide.

The application discloses a cytoskeleton reconstruction detection method, comprising the following steps: acquiring a continuous microscopic image sequence of a cell to be detected within a preset time window, pre-processing the image sequence and extracting a skeleton to obtain cytoskeleton structure data; based on the cytoskeleton structure data, constructing a cytoskeleton network graph at each time point, wherein the cytoskeleton network graph takes skeleton key structure points as nodes and takes skeleton fiber connection relationships as edges to form a time sequence graph structure; for the time sequence graph structure, extracting structure parameters reflecting node connection relationships and path distribution characteristics, and constructing a topological entropy function based on the structure parameters to form a structure dynamics signal; taking the structure dynamics signal as input, performing frequency domain transformation processing thereon to obtain corresponding frequency spectrum distribution characteristics; based on the frequency spectrum distribution characteristics, extracting parameters, and obtaining a cytoskeleton reconstruction judgment index based on the parameters. The application solves the technical problem that the prior art is difficult to capture subtle structure changes in a reconstruction starting stage.

The present invention relates to a corneal cell culture support comprising graphene and its uses. The graphene-containing support of the present invention is non-toxic to corneal cells, is optimized for the cell proliferation rate, adhesion rate, and survival rate of corneal cells, enhances the expression of corneal cell-specific genes, and can maintain an optimized corneal cell state through cytoskeletal remodeling and mitochondrial activation. Therefore, the corneal cell culture support has the effect of being utilized in cell therapies, implant materials in the field of regenerative medicine, and tissue engineering platforms.

The application belongs to the technical field of biological medicine, and particularly relates to application of a flavone small molecule compound in preparation of a drug for regulating WDR1 and / or treating leukemia. The flavone small molecule compound comprises Gambogic amide, Morellic acid, Flavopiridol hydrochloride, Gambogic Acid and / or Methylophiopogonanone B. The application research finds that the flavone small molecule compound such as Gambogic amide can effectively inhibit the activity of acute myeloid leukemia stem cells, and does not damage normal hematopoietic stem cells. The flavone small molecule compound is combined with WDR1 protein specifically expressed in the leukemia stem cells, induces cytoskeleton depolymerization, and further promotes the occurrence of leukemia stem cell apoptosis. The application provides a new direction for prevention and treatment of AML.

This invention provides a method, apparatus, device, and storage medium for generating cell motion trajectory curves. The method includes: acquiring multiple diffraction ring images of microspheres engulfed by cells; determining multiple three-dimensional coordinates of the microspheres based on the multiple diffraction ring images; determining the multiple three-dimensional coordinates of the microspheres as multiple three-dimensional coordinates of the cell; and generating a three-dimensional motion trajectory curve of the cell based on the multiple three-dimensional coordinates of the cell. This allows for the acquisition of multiple diffraction ring images of microspheres engulfed by cells and the automatic determination of multiple three-dimensional coordinates of the microspheres in the multiple diffraction ring images. Because the cell engulfs the microspheres, the microspheres are subject to dual constraints from the cell's cytoskeleton and cell membrane, allowing the microspheres to effectively track and reproduce changes in cell motion. The three-dimensional motion trajectory curve of the cell more realistically reflects changes in cell motion in three-dimensional space, increasing the realism of the cell motion changes reflected by the three-dimensional motion trajectory curve.

The application belongs to the technical field of biotechnology, and particularly relates to a high-efficiency expression of a Kluyveromyces marxianus strain and application thereof. The Kluyveromyces marxianus strain is obtained by using CRISPR / Cas9 gene editing technology to knock out genes in a protein synthesis metabolic pathway, a secretion and transport pathway, a cytoskeleton synthesis or an intercellular information transmission pathway in a genome of the Kluyveromyces marxianus, and taking the Kluyveromyces marxianus FIM-1 in which a key gene URA3 of a uracil synthesis pathway is knocked out as a starting strain. A FIM-1 ura3Delta mnn11Delta is screened and obtained, and the alpha-galactosidase secretion expression level can be increased by more than 3 times. The Kluyveromyces marxianus strain can be applied to high-efficiency preparation of biological enzymes such as alpha-galactosidase, ferulic acid esterase, chitosanase, saccharifying enzyme, xylanase, mannanase, cellulase and beta-amylase, and has high industrial application value.